RhythmOne Launches its Programmatic Platform in Asia-Pacific and Latin America
11.9.2019 08:30:00 EEST | Business Wire | Press release
RhythmOne, LLC, a Tremor International company, today announces it will be bringing the infrastructure, scale and success of its programmatic platform to the Asia-Pacific (APAC) and Latin American (LATAM) markets. The announcement will also be made at the international digital marketing conference DMEXCO, following the company’s successful expansion into Europe earlier this year.
To lead international expansion efforts, today the company also announces the appointment of industry veterans Assaf Suprasky as General Manager of Tremor International’s Israel operations and Gal Topaz as Senior Vice President, Exchange Operations and Business Development. Both executives come to RhythmOne with deep experience in advanced mobile and digital video advertising solutions. Prior to his role at RhythmOne, Suprasky was CEO at personalized advertising specialist myThings, and Topaz was the CEO of programmatic group Feature Forward. Physical business development and sales teams are also now in place and active in Europe, APAC, and LATAM.
The RhythmOne Programmatic Platform is among the world’s largest brand-safe programmatic platforms. Offering technological efficiency at virtually every stage of the process, the global platform helps to effectively connect buyers to sellers and engage consumers on formats spanning video, connected TV (CTV), in-app, and display. A proven leader in the US, the RhythmOne Programmatic Platform reaches 358.8 million uniques globally* and is directly integrated with 600+ premium publishers – resulting in over 10,000 properties. The April 2019 acquisition of RhythmOne by Tremor International (AIM: TRMR) has laid the groundwork for further expansion initiatives and enhancements to the platform, including leveraging the large geographical footprint of the group’s performance division by expanding the RhythmOne Programmatic Platform into Asia.
With brand safety at the heart of its offering – supported by RhythmGuard, RhythmOne’s proprietary brand safety technology – and consistent top-tier ratings in Pixalate’s Seller Trust Indexes for programmatic display, mobile, and video advertising both internationally and in the US, the RhythmOne Programmatic Platform helps deliver high-quality solutions with large scale, and is integrated with the major international players including Google Exchange Bidding and Amazon A9. For publishers, RhythmOne offers a fully-integrated supply monetization platform (SSP) to maximize the value of inventory across desktop, mobile, and connected TV devices. Powered by an enhanced technology stack, the RhythmOne SSP provides web publishers and app developers with full access to a global programmatic ad marketplace.
“We are proud to be hosting a large-scale presence at DMEXCO this year as we take our US success and bring it to the international stage in the Asia-Pacific and Latin American markets,” said Ofer Druker, CEO Tremor International. “Our platform has massive global reach, has unique features and partnerships, and, alongside our market-specific business development professionals, we provide the perfect combination of a world-class product with local support, giving us confidence in delivering our product on an international scale. We are also pleased to welcome Assaf Suprasky and Gal Topaz to the RhythmOne team and are confident that their expertise will help bolster our success by delivering results to both demand clients and supply partners on the global stage.”
*Quantcast Measure, August 2019 / 30 Day Total
-ENDS-
Notes to the editors
RhythmOne is top-rated in the most current Pixalate programmatic seller trust rankings (Q4 2018):
- #1 US and #4 International, Global Seller Trust Index
- #1 Mobile Seller Trust Index
- #1 US and #2 International, Video Seller Trust Index
Since 2018, RhythmOne has been partnered with AU-based Allegiant Media as a reseller for RhythmOne in Australia and New Zealand. RhythmOne will be continuing its partnership with them.
About Tremor International
Tremor International Ltd is a global leader in advertising technologies, operating in more than 70 countries. It has three core divisions: Tremor Video (brand advertising), RhythmOne (media) and Taptica (performance advertising).
RhythmOne drives real business outcomes in multiscreen advertising. Its highly-ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners – and its influencer marketing offering fosters action and awareness by connecting brands with influencers who create and distribute branded content to engaged consumers.
Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of creative video intelligence—innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, influencer marketing, and private marketplaces.
The Taptica performance business is an end-to-end mobile technology advertising platform that helps the world's top brands reach their most valuable users with the widest range of traffic sources available today. Its proprietary technology leverages big data to target quality media at scale. It works with more than 600 advertisers including Amazon, Alibaba, Bytedance, Netmarble, Stubhub and OpenTable.
Tremor International Ltd is headquartered in Israel and maintains offices throughout the US and Canada, Asia-Pacific, Europe, India, and Latin America, and is traded on the London Stock Exchange (AIM: TRMR).
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," “likely,” "will," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. All statements other than statements of historical fact are statements that could be forward-looking statements, including, but not limited to, statements about the potential and effectiveness of RhythmOne’s programmatic platform. These forward-looking statements are subject to risks and uncertainties, assumptions and other factors that could cause actual results and the timing of events to differ materially from future results that are expressed or implied in the forward-looking statements. Factors that could cause or contribute to such differences include the dynamic and rapidly evolving sector, as well as the highly competitive industry that RhythmOne operates in, which make it difficult to evaluate prospects. These and other risk factors are discussed in RhythmOne’s Annual Report for the period ended March 31, 2018. The forward-looking statements in this article are based on information available to RhythmOne as of the date hereof, and we assume no obligation to update any forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005104/en/
Contact information
For more information about RhythmOne and Tremor International
Jocelyn Wright or Emma Cheshire
Tremor@propellergroup.com
02033015353
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
